Unorthodox approach to the development of a new antituberculosis therapy.
Barry
Clifton E
CE
D000995:Antitubercular Agents / Q000627:therapeutic use*; D064687:Diarylquinolines; D055808:Drug Discovery / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D011804:Quinolines / Q000627:therapeutic use*; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
D000995:Antitubercular Agents; D064687:Diarylquinolines; D011804:Quinolines; C493870:bedaquiline